Safety and Effectiveness of Biktarvy ® (bictegravir/emtricitabine/tenofovir alafenamide) in Patients with HIV-1 Infection: Interim Report of a Post-Marketing Surveillance Study in Korea

This is the authors' abstract. We don't add key points for this paper.

year surveillance period of a prospective, multicenter, observational, post-marketing surveillance study that evaluates the safety and effectiveness of Biktarvy in routine clinical practice in Korea. A total of 1,157 patients were included in the safety analysis set. Most patients were male (93.3%) and ART experienced (treatment-experienced [89.3%]). Adverse events occurred in 425 patients (36.7%) and of those 63 patients reported adverse drug reactions (ADRs [5.5%]). No serious ADRs were reported. The virological success rate (HIV-1 RNA <50 copies/mL) of Biktarvy treatment at last visit was 96.7%.